<SEC-DOCUMENT>0001437749-21-026281.txt : 20211112
<SEC-HEADER>0001437749-21-026281.hdr.sgml : 20211112
<ACCEPTANCE-DATETIME>20211112073020
ACCESSION NUMBER:		0001437749-21-026281
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20211112
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211112
DATE AS OF CHANGE:		20211112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		211399577

	BUSINESS ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mbrx20211106_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:mbrx="http://www.mbrx.com/20211112"><head>
	<title>mbrx20211106_8k.htm</title>
	<!-- Generated by ThunderDome Portal - 11/9/2021 3:21:20 AM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20218K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20218K" name="dei:EntityCentralIndexKey">0001659617</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="mbrx-20211112.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20218K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-11-12</xbrli:startDate>
<xbrli:endDate>2021-11-12</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;"><b>WASHINGTON, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;"><b>FORM <ix:nonNumeric contextRef="d20218K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;"><b>PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;"><b>DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): <ix:nonNumeric contextRef="d20218K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b>November&#xa0;12, 2021</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="text-align: center;"><img alt="moleculinlogoresizedclear.jpg" src="moleculinlogoresizedclear.jpg" /></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityRegistrantName"><b>MOLECULIN BIOTECH, INC.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;">(Exact Name of Registrant as Specified in its Charter)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:2.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="text-transform:uppercase;">delaware</span></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:2.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityFileNumber"><b>001-37758</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:2.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityTaxIdentificationNumber"><b>47-4671997</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:2.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation or Organization)</div>
			</td>
			<td style="vertical-align:top;width:2.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File No.)</div>
			</td>
			<td style="vertical-align:top;width:2.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;"><b><ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressAddressLine1"><b>5300 Memorial Drive</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressAddressLine2"><b>Suite 950</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressCityOrTown"><b>Houston</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressStateOrProvince"><b>TX</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressPostalZipCode"><b>77007</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;">(Address of principal executive offices and zip code)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;"><b>(<ix:nonNumeric contextRef="d20218K" name="dei:CityAreaCode"><b>713</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20218K" name="dei:LocalPhoneNumber"><b>300-5160</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;">(Registrant&#8217;s telephone number, including area code)</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;">(Former name or former address, if changed from last report)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 32pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction A.2. below):</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:6.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric>&#xa0;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:6.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric>&#xa0;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:6.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric>&#xa0;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:6.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric>&#xa0;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 32pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#xa0; Emerging growth company <ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 32pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 32pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol (s)</b></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $.001 per share</div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:TradingSymbol">MBRX</ix:nonNumeric></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20218K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> Stock Market LLC</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Item 2.02</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Results of Operations and Financial Condition.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 24pt;text-indent:36pt;">On November 11, 2021, Moleculin Biotech, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter ended September 30, 2021&#xa0;and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>Item 9.01 </b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Financial Statements and Exhibits.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 24pt;">(d)&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Exhibits.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:1.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit No. </b></div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>&#xa0;Description</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:1.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">99.1</div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;&#xa0;<a href="ex_303877.htm" style="-sec-extract:exhibit;">Press Release dated November 11, 2021</a></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:1.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0; &#xa0;Cover page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;"><b><span style="text-decoration: underline;">SIGNATURE</span></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 24pt;text-indent:36pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:3.5%;">&#xa0;</td>
			<td style="vertical-align:middle;width:3.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>MOLECULIN BIOTECH, INC.</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.5%;">&#xa0;</td>
			<td style="vertical-align:middle;width:3.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.5%;">&#xa0;</td>
			<td style="vertical-align:middle;width:3.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.5%;">&#xa0;</td>
			<td style="vertical-align:middle;width:3.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: November&#xa0;12, 2021</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.5%;">&#xa0;</td>
			<td style="vertical-align:middle;width:3.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.5%;">&#xa0;</td>
			<td style="vertical-align:middle;width:3.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By: <span style="text-decoration: underline;">/s/ Jonathan P. Foster</span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.5%;">&#xa0;</td>
			<td style="vertical-align:middle;width:3.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jonathan P. Foster</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Financial Officer</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center;">2</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_303877.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_303877.htm</title>
	<!-- Generated by ThunderDome Portal - 11/9/2021 6:42:51 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 99.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="ex_303877img001.jpg" src="ex_303877img001.jpg" style="width:227;height:60;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>&#8211; Up to six clinical trials expected to be underway or with regulatory clearance by the end of 2021 </i>&#8211;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>&#8211; Preliminary clinical activity for Annamycin seen in interim results from its US Phase 1b/2 clinical trial for the treatment of soft tissue sarcoma (STS) lung metastases </i>&#8211;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>&#8211;STS lung metastases trial continues to recruit rapidly </i>&#8211;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>&#8211; Received favorable opinion from the MHRA to commence first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19, expected to commence in Q4 2021 </i>&#8211;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>&#8211; Additional key clinical and regulatory milestones expected throughout the next 18 months </i>&#8211;<i> </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>HOUSTON, November 11, 2021 /PRNewswire/ -- Moleculin Biotech, Inc.</b>, (Nasdaq: MBRX) (Moleculin, we or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended September 30, 2021. The Company also provided an update on its portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;With up to six clinical trials that are either currently underway or expected to have regulatory clearance by the end of 2021, we have made tremendous fundamental progress, and this is truly an exciting time at Moleculin. Furthermore, we believe at least one additional trial will be approved in early 2022. We continue to be encouraged by both the demonstrated potential and data seen across our portfolio of drug candidates,&#8221; commented Walter Klemp, Chairman and CEO of Moleculin.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">He continued &#8220;We are extremely pleased that the STS lung metastases trial recently expanded to a total of three sites and that we are now in the third cohort with the first patient already treated and the final two patients in screening. This trial continues to recruit rapidly, and, on this pace, we could see the Phase 2 begin in the first half of 2022.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Concluding, he added &#8220;The unmet medical needs that people with highly resistant tumors and viruses are faced with continue to be a driving force as we work to develop safe and effective treatments in a number of oncology and viral indications. We are dedicated to advancing our three core technologies and, I believe, are well-positioned to achieve the key value drivers we expect to see over the next 18 months.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Recent Highlights </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Received authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a Phase 1a clinical trial of WP1122 in the United Kingdom for inhibition of viral replication and disease manifestations in humans infected with SARS-CoV-2, the virus responsible for COVID-19. The Company also announced it has received a favorable opinion from the London - Riverside Research Ethics Committee in the UK to begin the study, which is expected to be conducted at the Medicines Evaluation Unit in Manchester, United Kingdom.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reported interim results from its U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases, which documented preliminary clinical activity for Annamycin.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Programs Update </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Next Generation Anthracycline - Annamycin</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Annamycin, the Company&#8217;s next-generation anthracycline was designed to be noncardiotoxic (unlike all currently approved anthracyclines) and has demonstrated its lack of cardiotoxicity in recently conducted human clinical trials for the treatment of AML. The Company believes that, because of this unique improvement in safety, the use of Annamycin may not face the same usage limitations imposed on doxorubicin and other currently approved anthracyclines. Additionally, Annamycin has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin. Annamycin is currently in development for the treatment of AML and STS lung metastases.&nbsp;For more information about the Phase 1b/2 study evaluating Annamycin for the treatment of STS lung metastases, please visit clinicaltrials.gov and reference identifier NCT04887298.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Upcoming Milestones Expectations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H2 2021: Report cohort topline results from the ongoing Phase 1/2 study for treatment of AML and report the study's topline results.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H2 2021: Report cohort topline results from the ongoing Phase 1/2 study for treatment of STS lung metastases and report the study's topline results.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H2 2021: Initiate Phase 1/2 study in Europe for the treatment of AML evaluating combination therapy of Annamycin + Ara-C.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H1 2022: Commencement of an investigator-funded, second Phase 1b/2 clinical trial of Annamycin in sarcoma lung metastases in Europe.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H1 2022: Complete Phase 1b portion of ongoing Phase 1b/2 study of Annamycin for the treatment of sarcoma lung metastases in the US.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>First-in-class p-STAT3 inhibitors - WP1066 and WP1220</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">WP1066 is one of several Immune/Transcription Modulators, designed to stimulate the immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3 (phosphorylated signal transducer and activator of transcription 3), c-Myc (a cellular signal transducer named after a homologous avian virus called Myelocytomatosis) and HIF-1&#945; (hypoxia inducible factor 1&#945;). These transcription factors are widely sought targets that are believed to contribute to an increase in cell survival and proliferation, and the angiogenesis (coopting vasculature for blood supply), invasion, metastasis and inflammation associated with tumors. They may also play a role in the inability of immune checkpoint inhibitors to affect more resistant tumors. WP1220 is a close analog to WP1066 that the Company has developed as a potential topical therapy for skin-related diseases.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">WP1220 was evaluated for the treatment of Cutaneous T-Cell Lymphoma (CTCL) and, based on those results, we are seeking collaborators for future development. WP1066 is currently being evaluated for the treatment of pediatric brain tumors, including Diffuse Interstitial Pontine Glioma (DIPG). Additionally, WP1066 + radiation is being evaluated, pre-clinically, in the treatment of Glioblastoma Multiforme (GBM).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Upcoming Milestones Expectations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H2 2021: File a US Investigational New Drug application (IND) for the treatment of certain adult cancer(s) with WP1066 and begin to identify an institution to commence an associated investigator-funded Phase 1a/1b study.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H1 2022: Report topline results from Phase 1 physician-sponsored pediatric brain tumor clinical trial.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H2 2022: Facilitate&nbsp;launch&nbsp;of physician-sponsored Phase 2 study of WP1066 for the treatment of pediatric brain tumors including DIPG.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Actively seek collaboration with a strategic partner in the near term for external funding for the continued development of WP1220 in a Phase 2 clinical trial as a topical therapy for CTCL.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Infectious Disease and Metabolism/Glycosylation Inhibitors- WP1122, WP1096 and WP1097 Portfolio</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Moleculin has new compounds designed to target the roles of glycolysis and glycosylation in both cancer and viral diseases. The Company&#8217;s lead Metabolism/Glycosylation Inhibitor, WP1122, is a prodrug of 2-DG that appears to improve the drug-like properties of 2-DG by increasing its circulation time and improving tissue/organ distribution.&nbsp;Based on recently published research that has identified that 2-DG has antiviral potential against SARS-CoV-2 <i>in vitro</i>, Moleculin believes WP1122 has significant potential as a COVID-19 therapy.&nbsp; Its unique mechanism of action may also be well-suited for combinations that potentiate existing therapies, including checkpoint inhibitors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company recently received authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a Phase 1a clinical trial of WP1122 in the United Kingdom. The Company also received a favorable opinion from the London - Riverside Research Ethics Committee in the UK to begin the study, which is expected to be conducted at the Medicines Evaluation Unit in Manchester, United Kingdom. The Phase 1a study in healthy human volunteers will investigate the effects of a single ascending dose (SAD) and multiple days of ascending dosing (MAD) of WP1122 administered as an oral solution. Dose escalation will take place in sequential SAD cohorts, and MAD will start as soon as SAD has completed at least 3 dosing cohorts in which WP1122 is found to be safe and well-tolerated. This study in healthy volunteers will explore safety and pharmacokinetics (PK), and subsequent clinical development will be in patients infected with SARS-CoV-2 to further evaluate safety and establish a favorable risk/benefit profile. The Company expects to enroll approximately 80 healthy volunteers in the United Kingdom.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Additionally, the Company is in the process of identifying countries where potential future Phase 2 clinical studies could occur. The Company is also engaged in preclinical development of additional antimetabolites (WP1096 and WP1097) targeting glucose and mannose metabolism.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Upcoming Milestones Expectations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H2 2021: Commence Phase 1a study of WP1122 for the treatment of COVID-19 in the UK.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H2 2021: File an IND in the US for the treatment of certain cancers such as GBM and pancreatic cancer&nbsp;with WP1122.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">H1 2022: Potential to launch Phase 2 pivotal study of WP1122 for the treatment of COVID-19 outside of the US.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ongoing preclinical development work in anti-viral indications such as HIV, Zika, and Dengue. Collaborations targeted for 2022.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary of Financial Results for Third Quarter 2021</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Research and development (R&amp;D) expense was $4.1 million and $4.4 million for the three months ended September 30, 2021 and 2020, respectively. The decrease of $0.3 million is mainly related to the timing of costs incurred in 2020 of producing additional drug product for Annamycin clinical trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">General and administrative expense was $2.0 million and&nbsp;$1.7&nbsp;million for the three months ended September 30, 2021 and 2020, respectively. The increase of&nbsp;$0.3&nbsp;million is mainly related to an increase&nbsp;in consulting and advisory fees and an increase in our corporate insurance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">For the nine months ended September 30, 2021 and 2020, the Company incurred net losses of $13.1 million and $14.7 million, respectively, and had net cash flows used in operating activities of $14.7 million and $14.6 million, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company ended the quarter with $75.2 million of cash. The Company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase over its current R&amp;D rate of expenditures, into 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>About Moleculin Biotech, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to be noncardiotoxic and to avoid multidrug resistance mechanisms. In addition, Annamycin has been shown in animal models to reach higher concentration levels than doxorubicin (a leading anthracycline) in certain key organs, such as the lungs, liver and pancreas considered to be difficult-to-reach "sanctuary sites" for tumors. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.</p>

<p>For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="text-align: justify;">Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the Company&#8217; ability to have up to six clinical trials either underway or to have regulatory clearance by the end of 2021, and to have an additional trial approved in early 2022; the Company&#8217;s ability to meet the clinical trial milestones described in this release; whether the pre-clinical results for WP1122 described are able to be replicated in clinical trials; and the Company&#8217;s forecasted cash burn rate. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="margin: 0pt;">JTC Team, LLC</p>

<p style="margin: 0pt;">Jenene Thomas</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">(833) 475-8247</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">MBRX@jtcir.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 32pt;"><b>-- Financial Tables Follow--</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Moleculin Biotech, Inc.</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 99px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 92px;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Unaudited Condensed Consolidated Balance Sheets</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 99px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 92px;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(in thousands)</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 116px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>September 30, 2021</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 111px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>December 31, 2020</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current assets:</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 99px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 92px;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash and cash equivalents</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 14px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">75,178</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 19px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">15,173</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prepaid expenses and other current assets</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,892</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,025</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total current assets</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">77,070</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">17,198</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furniture and equipment, net</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">353</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">483</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Intangible assets</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,148</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,148</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating lease right-of-use asset</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">131</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">202</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 14px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">88,702</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 19px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">29,031</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 1030px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 99px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 92px;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current liabilities:</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 99px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 92px;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accounts payable and accrued expenses and other current liabilities</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3,656</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 19px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,920</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total current liabilities</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3,656</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,920</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating lease liability - long-term, net of current portion</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">75</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">159</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Warrant liability - long term</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3,712</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,192</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total liabilities</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7,443</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,271</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stockholders' equity</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">81,259</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 19px;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">17,760</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 1030px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total liabilities and stockholders' equity</p>
			</td>
			<td style="vertical-align: bottom; width: 124px;">&nbsp;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 14px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 99px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">88,702</p>
			</td>
			<td style="vertical-align: bottom; width: 7px;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5px;">&nbsp;</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 19px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 92px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">29,031</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Unaudited Condensed Consolidated Statements of Operations</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td colspan="6" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Three Months Ended September 30,</b></p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td colspan="6" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Nine Months Ended September, 30</b></p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(in thousands, except share and per share amounts)</b></p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021</b></p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2020</b></p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021</b></p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2020</b></p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenues</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating expenses:</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4,095</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4,435</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,239</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10,971</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General and administrative and depreciation</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,062</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,716</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,524</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5,276</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total operating expenses</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,157</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,151</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">17,763</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">16,247</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Loss from operations</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(6,157</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(6,151</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(17,763</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(16,247</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other income:</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Gain from change in fair value of warrant liability</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,678</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,743</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4,428</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,489</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other income, net</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">13</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">30</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">32</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest income, net</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">87</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">236</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss</p>
			</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(4,379</p>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(3,395</p>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(13,069</p>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(14,716</p>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss per common share - basic and diluted</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(0.15</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(0.33</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(0.50</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(1.55</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Weighted average common shares outstanding - basic and diluted</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">28,573,476</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10,245,810</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">26,302,638</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">9,496,585</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mbrx-20211112.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/9/2021 6:37:48 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:mbrx="http://www.mbrx.com/20211112" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.mbrx.com/20211112">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20211112_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20211112_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20211112_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.mbrx.com/20211112/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="mbrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>mbrx-20211112_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/9/2021 6:37:48 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.mbrx.com/20211112/role/statement-document-and-entity-information" xlink:href="mbrx-20211112.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.mbrx.com/20211112/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mbrx-20211112_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/9/2021 6:37:48 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line Two</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:label xlink:label="dei_EntityExTransitionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Ex Transition Period</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mbrx-20211112_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/9/2021 6:37:48 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.mbrx.com/20211112/role/statement-document-and-entity-information" xlink:href="mbrx-20211112.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.mbrx.com/20211112/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex_303877img001.jpg
<TEXT>
begin 644 ex_303877img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ .,# 2(  A$! Q$!_\0
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M.'7)4]HM8HQJUWST^1Z29[A17$^(OB/8Z-?MI]I:R7]XC;'"-M56_NYP23[
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M\I-='M5&='M:S_ P5*4H5M-;W7WG#^)[E?&7C[3=.MVWVVV./@]F'F2'_OG
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M1117,=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>moleculinlogoresizedclear.jpg
<TEXT>
begin 644 moleculinlogoresizedclear.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0"L17AI9@  34T *@    @ !0$2  ,
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M>'!A8VME="!E;F0](G<B/SX _^T .%!H;W1O<VAO<" S+C  .$))300$
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M_C+3AQ)X#5LVS-)XY8'+\:GHK5Y?5>9I+176+KQLE9*5DDDD?P1X.TO]5_I
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MQ.(KU(=I5)R7W.37]?=G2P6#HRYJ-*G"7>,8I_@E_7X]O7 =(4 % !0 4 %
B!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>mbrx20211106_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbrx-20211112.xsd" xlink:type="simple"/>
    <context id="d20218K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2021-11-12</startDate>
            <endDate>2021-11-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20218K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20218K">0001659617</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20218K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20218K">2021-11-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20218K">MOLECULIN BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20218K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20218K">001-37758</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20218K">47-4671997</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20218K">5300 Memorial Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="d20218K">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="d20218K">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20218K">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20218K">77007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20218K">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20218K">300-5160</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20218K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20218K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20218K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20218K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="d20218K">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="d20218K">true</dei:EntityExTransitionPeriod>
    <dei:Security12bTitle contextRef="d20218K">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20218K">MBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20218K">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139855494347512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">MOLECULIN BIOTECH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Nov. 12,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">47-4671997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">5300 Memorial Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity, Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">77007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-5160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity, Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001659617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MR>IPZ#\\&+G-#MI+:>#8GMUN& 6WL@7@^TI*<WJP9_?\KY?!/U!+ P04
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M2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @ R3ML4R0>FZ*M    ^ $  !H
M  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50J4,%
M3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*9,OL
M[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]
MLCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP
M3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( ,D[;%-ED'F2&0$  ,\#
M   3    6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@
M"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"
M50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-
M\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[
M0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TF
MGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D<WC
M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ R3ML4P=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " #).VQ3?X>J_NT    K @  $0
M    @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #).VQ3F5R<
M(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM
M;%!+ 0(4 Q0    ( ,D[;%,L7TU67@0  (81   8              " @0P(
M  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #).VQ3GZ ;
M\+$"  #B#   #0              @ &@#   >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( ,D[;%.7BKL<P    !,"   +              "  7P/  !?<F5L
M<R\N<F5L<U!+ 0(4 Q0    ( ,D[;%,ZJJ+G0 $  #P"   /
M  "  640  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #).VQ3)!Z;HJT
M  #X 0  &@              @ '2$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " #).VQ399!YDAD!  #/ P  $P
M@ &W$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   !%
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mbrx20211106_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mbrx.com/20211112/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mbrx20211106_8k.htm">mbrx20211106_8k.htm</File>
    <File>ex_303877.htm</File>
    <File>mbrx-20211112.xsd</File>
    <File>mbrx-20211112_def.xml</File>
    <File>mbrx-20211112_lab.xml</File>
    <File>mbrx-20211112_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>moleculinlogoresizedclear.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mbrx20211106_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "mbrx-20211112_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mbrx20211106_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mbrx-20211112_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbrx-20211112_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mbrx-20211112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 28,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mbrx",
   "nsuri": "http://www.mbrx.com/20211112",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20211106_8k.htm",
      "contextRef": "d20218K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.mbrx.com/20211112/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20211106_8k.htm",
      "contextRef": "d20218K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity, Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity, Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.mbrx.com/20211112/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001437749-21-026281-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-21-026281-xbrl.zip
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MZ#! (F N.<*-M.$%[!#5K$PI0+X9H837'L%FK=)5KO9"N&A;DE\J7VFU,!]
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MR_BD.6)9'EWJ4M<.?7( (WG@HWGZ(P@?K3P8+12A$UVC2U)H:C51]_>3BVM
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M^*GIIR4Q+3 Q_6YRE^\SDZ@E%Q5=Q[)RIZM6QIX^G_[;8O\KK[FV]H_  $O
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M*<U3>VE\V9,U/#HF:YN\>(-!,E8P@1 W";A"$T"0LR!+STU!"",AF6J577H
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M[IUY!ESET"1=@GT.BL3.!&":7#UXJ=Q_J4!_X3%\H0A^J6R=I=!\A,HW-HC
MYYC*,>))>3[X 5.4;[BKTQ-F3N]OM^M?7K [<YC>BG63PV9XM>T-J][>>L&2
MY^+\SBDV&]/&9AVQV2RE[GA<GH<BX*!.F4JLZ.Y;?HU ?E/^M(CF^C1)V-K:
M;LPO/UI$DWZ*V&M8M<;&C/C/?.M#68!VFP!U12T.ILAVIF,&3%-S:5NU=FU^
M.<5T+(]I<N:V5=^>1%5\5\K%IR3TJ5I2]W$$8X<J/RPLMBT/]B1TUMR81(,M
M3_7+H-W:FI6],-_R&D8^]6-\LYQ.GRX%],3RHF[56POO6EB@HSPQP-^5@/X]
MZY:@LYL)@!75K>#K[^A\EV;_#)E%LSZ_G*(T^A\V^FN3.&S>CPHQUN2?OH>Q
M"73DJ(0:R3^#U\S(M_Y*FY@^)]O:LMH3'8C9,K-G4\=,(R^O11W3YY7;5FTB
M43>'.MKS5>HY,8+*9(4R6>&^E!Q7ZL)S*<J\G)+4E](2/K#I_341"_A -P?
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MU=PMET5*%PGA%B9N)ANALC]'+.R=Q(/8>K/[B&3_Y2X^^1]02P,$%     @
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MI\X'O5OO)B-+AC>;+VD-AWO/LW+U4O;PY]91$/XCU@K]7KSZ_P%02P,$%
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M4M!]MT9J9;BX$">N?0?U_6W,4/ZE-&>L*^CLZ\'W&<ZIB< 28],$YT$=UNC
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MYVHQ[<#+?H=<+,-FI7M3.U@SGXQTWO YTR#)_K["767N3OFT%='WQ@K9!C1
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M(-JRTL$]]_NS]^6S%ZR3/U'NH*Y15(E_@Z^S<I)E@:PJ^03#9%8<5^R%3+_
MK)7]H#2G&_H90/%OB(\63)"57SFL?_#4J.*J"=(!TL*^T,E1O_".X9)U_Z$@
MCAB%B!BE7)74Y1IL3?K6X9SK8IY^AA\%I(E]T6&BB$U$1UL*24JBE"WI^V 6
M"3/.#''^2_%#I&2EDU'RI>,'NZ?+2^TX>'.GY7'RD,EDX3/K/6#,4=BUFS3
MHWU7&J!)\?!9N\"A01%X7_5K>*CIL<YQX"GFO8-\-#"YLH\F";0.Q$$KKL:3
M4%VF:RVL0!^JX(P[BO[G\N@'4GJDO/O8N"*YN<WQZ>/!!=W:6Y.##W4GH_#(
M7(0R,3L)7ALA0;IJT*[0N].A0;)0)WFF#QY\'$+_E/6<S_=JFL/\LHYMEB+J
M7_1SP5,V1.$S8P7B8/?W,8BYR1WS^""[U(/49,LK96+<DRUV)Y7(A8IY5N3#
M^:1:)%WC;:)B%[]2<P4Q\P7H?K/0=Y#M0BF'WM5F14=3+VFC3U\"O$*8LMR'
M!/H0W#67OQ+_1@*!B&?525S1F1P/*OED^=,J.+'/--(V^D,^O%N2&HY,-5NQ
MLI\W]"A;A[]<K&4E^^1V"?;)O8FK7M++U14W3A#R2(*P>9>L%4Q'5K=(FRUG
M)SR9_T8#\($7%LH8R<!VH!\Q8/\1J:R#-?*^9RT_?S6YEU"*M";[X<'7/*Q$
M4N_7DL,4X&<[K'C+4D5*V]IK,S.LS0Y%FOLK**/[",5?UEV/;9R,;_3[3O#?
M"$S7C\!<?"AEFM#,%>LTEX.=SY*ITRXP2Z^OKT(R=J @][X(8_FL=%,)%125
M]0;#:^K&4;RC0GU]3-)-439CGBG(*VN.G8/+UIY[)OO73IJ:F</GP*Q[J*L4
MI63;TVG=>/V9RT?$WTXW&E2Y #O<>,,R^EDB[\&6G>7HS]1/\ "GZ*$ ET*[
M'I?TK>7H.]'+E]XEDX#L"#D"D"G #LZT,3G:]E!P28?-,'MRU!1FK)+CHF;Q
M<<I2HENT/E^D[U*;_TD9KH6=[-G>6!2:I*-2/ BS>J]*;Y6IJBJ4*8SA8HA3
M"%SA498R@*GURQ^'MZB!M<&T82H>#-N.YJ# 3G*UU"DBE5F$Z?OD>"*J:XYU
MZ&>IJ[NW5Y!7 ,XN,2,UX%RA3I<T;]IKA?(;6![.7SD".5TQ\#*9@<?YDG!0
M$,-00OI(OG&!J_"X!2'++:)#76> ["GWYZ*Z>8;B>;NXE&K"NGG:E?2?G[*-
M')4_8C>1*%4<:MI\_RN9JZ@@[^S)NW 5LNQ^]QVNAO,#20B=3VM7Q[]_+J7F
M(A>V8Q7AE;@S7JKW7QB&LI6<%>KLN:M^]L2F#Z%(W'U)'/OF7U+)!C$F87F5
MUKH[* J)3U0K"D<^C*3N)RH-UW0=*L>0XMO[6?MR02IN;]HLWBW@-:I=^=V\
MO3UL6GSX/0(2WA/U#+"Z38/'SX[%D*VX<-6A[5_;C-3Q/+IAA,O[/B65(<1]
MLO5'3 S%\6.7D'W[>,,![DOQ="YC.['3]L?;7_%?&#]?F% ZS&9 9L.W5[.?
MYTHLUC%R:G!'9A_52#K\0GM^T6'CQIK[W$FW,6:TUB#9(^_!0WXU'XW"72DA
MT1%F:0^+\8O=RN&ZH=_3EGCCW_;50CY@/?6X8=4A)YH4;C*>F+\?3;P03])9
M&$@*!,;RTX^_IG:4KEJ+ZD8O2S,V25F5Y]X<J9(), GXO-ZVSPV4*3C_*/'N
M5ZH<@?_:@)JY<G&*'POO)R[%#R>K1O;Z51]&%]4,/'E:ZPQL.ZH&3S"O_"X8
M=O!8\NW>:!_N< U:0#.\>JITI+0EWNTE;J!G&F(6!T-_1^B0_1: \5J7QRAT
M),56ZG72_(M&?9A(1BT^^<J:2E9_8N%TP^OC8ZF)'PE&;+<^I*OT,OZQVO.5
MK3?]\62>?C(FZ]'>AG,EK\)R%,3<-\=NO:#DQ I;RNNI/_[&=8)IFMY<MD]\
MJ/V!1^<PQDS2-V63\!.UMT/5H $6"FD HKZFRS[T\RA5,[P_WX$4\E7**H,&
MZ)CC:ZYK&$.X$#W.+/6_#RGL<1T!61/'9LJ9L?>@9H.9%PY_>H7,V=$ [[0N
MA=T4)R7:(60ZJ#TQ')!!M)F$=H8,#2 95P5[* #Q@^2&8?5RG>R"D /)UZF)
MR3%RPX2?])8>KDK3Z1Y>]2.XKG!OM]"1?('#0]%U4[N1@(+Z5<H\#7"NFP9X
MD07?WA<@G;1$@1R#2N"H_4"2506*GWP=-+W1PC@W!V'?)0C\(=UO5/ORR<!V
MD(R&3(4G40K1,G5&0N2(!N %<?6"]'OF7#/T<OFE\TT.E ,A)69#42'HM2:L
MQ=/OP4;'C(4(Y!]4T&,$?=;IM$L*P.*J)?W[%;ZDJZNZF:$L334];DM96\/"
M7.SF9\LB$8[X9 &R.6Y.E>CTY2,<U:8E,QBXS0;W;+=3'@EIL*I]O[[_VFDM
M*P\5Q*$4,#5G=^]3 JM./XLN\JW:)HNB=.=H;R6O>7[R>S.+=?,LOQRQ"R/Y
MXDWF\4;*,S2 ,1'^3=0E$IW\U2+J":>'7ZYZ*U;;-\4L(5\D/R'52+G!C:1Y
M'$H#]'A7#QRK@R<.:( [X?W5U 3RZ<8G/FI";9]LH?XRV<U/:EF2DA?85^AI
M^950?A1#9>Q;8'99<-OR.R6.S<2@?)T0PG6Q.R/,/;HU F1;&J 2$R<-LL7_
M2%E6GF4>CZ4H%]Z^))SR'?;D@O:K<*%5W-OO!.]S?8W@KMX9C'HQ%%K\^ I:
M+[_6$E(0FGE0=/@Q/.K7FUXW7(Y7"CDJ*M*AJ7/F/;R(S%#,!MF%$(,D>CRV
M74UFF[(R4>&S>>K#IW6'1A+-H9.X!>B+ZHM[R!C&?(0$T:4Z=SK;]"-\Q:B*
MO$@:.I**=]Q5JFEA?5 SG)OIGK33FB]\V6\=[IQI342V)BS&57)KA/;FB7YN
M&(4DY#&>R4I/H0%@:>N>P7CAS2,B_'WR>T)7PB'XP@/)HK=WA&(BAXHWAQ-M
M2KSEVWR-"PK*RS'G/BS4?\K)^.P(I/!Y>GJYD(KW0RHJHV]YW@)/+A+.H]%5
MXD)Q<V/S'4>/5+[?B8A,XC:U8/EJ+3!XU1_[^O%NMK>/,D[EN!92.M^7"S6$
M=ZHGF7(7ZSZ0-W@:,*AE?5J[78B_D?A+%TTF[5LS5=F!,52^\#;H!>5Y%IOR
MDS9/?K7O>UOV[;Q9^:[\AA_)H05M70+!P[ _U<IJCC1<;31XG(+>=(*W;/I%
MVX>QP)_WT\6UP<!2J_#/.UJWUF22.@B[E&0)+'B?05V9IU/%VKRHV"+MY_8X
M_6T1SV>?C6ZMG22&#R#IFZ_#Q?:A9$MB@!ZQ,VF>]0F5G6R/LW82R!N2*E6T
M+Q^A*#[*^M'0T=BZ."H+TE7^L3O7+1=2GQ42(OW-"(FBF**6)\NX%N$QG':8
M_>I[7I#FP5L0!<MKR4)62_<_WS?]'&<@PZY_@&+Y8>MDCN,V%F@UC?0O4M,(
M3%?YE*/.[F'=HICQR6BVNV;::Y8&N XEWLL^'GC10K1*OD!F;%5592-[;!!:
MMLX298\&'Z<$C2#..[-V<)?(_$2_>OM)J\N/B--M8+^EJ)21W6^3"IVG*@S'
ML,.9[56^#<&7GO>2L*NE3E#+99@,YYALXY/TE/04 V'D.?@MPQ/KH[_U"O<(
MX]-/7'BB?<GU6&"I^">8D]/V2/G6K=D=+<^:Z=_KRWURTD$;LC:XA;"E&;+.
MSTLV.':$Q_5HOH_,S +' )4-'TWYLVS$6R[FC.7=<H8M@J1P#SQ@D$^JDA%A
M:65<9/ &FLP8FR?04=++R9IT)<#V:=UH!&5\;WRE;.+L?@+Y+5%_/RUY,3,R
M_/Q\^&GI<] _1UB'-_!4D3Z6%D]X:H%0N(:8N'!A(;) *U5M/']$L+[QR_,5
M%4\&&L#K&Z_[E"[KOI84,=JP'<1#+76IO/OHK>K8FGYN@WQ$U'FK*^4T0$M9
M3(1#$;,^ZNWQQ6H>\9IFQC8MA?X=*+N?^IR %#;W<8M%L<C/T5P;R)?W&M46
M6-,RTV=#6<$OXO9W' 8;$II?G;0T2X0/S]<.))X6RW1[2WEF^W94P_@+BGHI
M&6S10IQOVTYV$OU"\HXH69^R0L,NE(44402(F\2R&-W2S>!"T(*Y1=WA*SZ!
M)&*9Z$(+H\*F-S2"D,"B$2U:(MFF+*_&8(HVNYQCG^"26(2J6HY(/0A",V]A
M9N%-\8L^5_P.PY6)_8KG[1DO#6/-U!!!D$JT^G"F)&IDK5N\4YG=X$O1\#0L
M=(5R!4,(Z4!>@;OL7R66M:\V&G[T1+$B'P"CL]#+KPE;MZP&&PU]%I'L4/+4
M0/M14C5ZPW=R/8.WKPTA.CCDFL>]PLPV>Y#XE,KTH_XJ(T\[F9(^F,?%U0%_
MHV>!YAD*E'C&!9%+ _)H3_1\DE7P@Q6'..DG'2:%Q-$ ECL./\T3'< LWP,L
M.2S'!#\4K1N;-XW4$RUJ[*K%0H)\-HH63WFYT/%M:BN8ON5T,>:T\\B"XNR!
MT:CSGP(-:0!ZAXDUZLW!,H0(FOS,KGPL4,;$=+C:W4N9&>*.-JR?NB1<7_LE
MUP&E_.:4W@R2.%ZJ0=MG0JX]0%]:,>]\>#AJ4Z_M48F]U.F;D!^85G8ERS3M
MX="!&;C!+US =X6-'!*U@'CDH2\4S<'(_4S=KL#RO/']- _#W-UG1;M>W7-V
MLS,4X&FM5X2W(QG!SL@)_58D*Y6-'$,0_8+?Y@N?F (G*W,WW]BP,Z[4RBUI
M/;Z%T"&FBB:+IKYS9_1Q"_JX:K4EV5-YZ]Y;IBOG!8;SSI&3<\F9A"0AE0&L
MLP2!.*,IR19X4USB]K+:TSD:0&DE5,(BQ<B_.+!IDE+]ZSGQ0)@XWL:KKG+;
MG /$C#BT\JC*5^5!/B; [!02;FPN0H#S >G3$(BD?/*Z->5R#@W0V02ZMD4R
M6:S3FB<%[ T/+'@2:8""6DHNPOKD^0/D'OOK$[I?SVB 5-OG-$!Y I2*M@*C
MMN,%=G+U3S>S?;(;#9!/Y;/>$V-=^^6,W+]'0/YJ-* 4=Z!VTNI,CL7E:( C
M%R;KDW+PDLK1RDF>]>;@J0/X<='X'^"E_\0D32XCET1/(=+$/-WADNXV6<:'
M4K#1 =X'4ON11W>K48.]U'N-X(U]E]/@VJ%WYP]!9!^B:\O14U<!,E 4B6]N
MO&<9ITJ1,'E1D5_&>LT(MEAW9[!\233FVUR"NC5@OY0:_Y3L @'Z;(%<*5M[
M;C[ZE3L^2RMA,AL@,#^.C9-+[8%OJ5A1R[&=R2CTK::,,$KG*/:D)OP* C0,
M7G@[7Z6*\P*W/95!O4"P'DN1!RDB^ TOK2F96[@#_K-$YOX*_+4FV4DA-MNY
M5;N:USX!Y_XL%C3A]M5Y-$YRBYZ<\[3O!*%42IU**OF,G^E,C?A[6VHVP3N+
M4IM^%.GY)Z0.?ARV E>!C'L^?U.->#MGK\^JZSKA$,.^9O8CN3*F'-<3&.KL
M;;FY=+%N:N:31*E9"SZ&<BTB0!'QZ*10D,7L&BI*@-'[QW.MNTS=B]NQ_/87
MHRU"#8,$,0>6L=O0H7G#"9&4'[FN?-XRH@>UY6W48.M?X!RM&.7KNMDCP<:!
M<CLP]T\;B_SQG[\8?@:73E$YP'7)M!$J]>+ X4GH3_&SY/C3DIZDMC8,;.Z1
M-BS)!PN)#'ID,=)*NVK6^HQ-1\-P*_*JLHM*/H$&N.A4("\=?#4/V&Q;W7<]
MF]%/L^.D'(<[8TA]%78-88KSTV?"12EJM)!>NZ:ER<AL.#N[#Q55?PET\5!&
M9K#E:^8:Z%-FCLS(^G'=NVM^'TT@AUH:&*64)GQL^BPD>%*R])F=@7*?F>5B
MR:Q:+[&_I9!U46@3/#&^/T$>/>9$F'\FOR1^<4CQ4MFQ-X1>IVB-;GMGMD+9
ME<1YN(Z![6.OI>==1V5NF"GU>5S,OC_D0&D.PV;U(/L1NL3A&)!>MTBZVY4T
M/S:CP;*+95XQV2U-1FMP58H=>WA_$1624^URS!6E!20)1$_N@8)YJ]9=APZD
M[N?,?RYE+):,M\ PVJ4'-J&%#\..K M.MPO62?/]]V278RB%B]C2.1 54MD<
M_TFZ1J,_ AO[D,3UHM$:\R092@QYN74SQ6:K.I=WZ>M,POY!\#;GZ)=N'R4S
MU4/73@I7KB\KFS6^<4?>ILA(K5]CN-38;K@48N?$8;>>EB\B;J3GEP+=$#M/
M2C+HRM'4>:G TV,CV8WAD;5+*]*=0DN^/E:,3#6!=]OY^D?FB_V2F467[I5V
MI&]5<66$^!IZ!L&"F$*NCJN,LU4I3L_8?RN]0C3A2 M\8)GV2N_20(]V $9$
MPPN+"1RN-'HR[&@^*F NWFGJEV(L8XNIU"<-'/O3 *T\B&<?PB>A+!3@L1SY
ML;L6,_7[T<E,%LM['U>_9_CM/W@S<F(L2-4Q<8YR&5KTQ/WD+Q;$A?36!DLO
MSHONI8B!7_0XDP(]6WO<M\=BB5(2?BR6!@$=W7H?M10\E!PU9XK[D0WM54TC
M8Q)8IR+HUSFQDVM^U91[7\?QO%H#-[\50[/8&GT#7J2M:U0TFN6?2R,>'0^9
M,&RQ/AK?0Q&M\0*16F<H0N10HMM7%1_7!1H@NIEML/'FNPXIKH:L8?W*I-FR
M;?3#/BUTD4-,??VK79'V_JX4/XI4N_HR^&7E-^CEQRDKW_S25ZSR[61AW5]T
M Q/"N=$?X@S<D0&/WFK1Q^P@9/4SNE+I(M\S6(S^/'3FY S>\YK::K+W:K*E
M)%&G:8"SS<H;**+-B5O74X'6EOBIE1>/3CZ 'VUI@[G=40S4FQO\[&&J^K7D
MBT&Y1@C+C_"'&SCD9(/ZT"?=F>5-70^OI5U;1&W704@,R 1GXY,_"L)PO%GZ
M5:F<]K@B$!.':RM3F@.G\/=86CJ%[N)2)+DRE4+-&UJ( SQ$-TY">$I0701K
MIHM;:J]\KUTI+R?:H#,7U#2"JK:8%>%^)AEGU*<LKC:U)7;\^G1'S#_)V8-.
ML>[?)#DT<Q#GB@DH <0-DDE,LQ3<1)=(S2WRF!,<]?HU'9_,0AZ_.QA8RCNU
M:SI:ML=Z!IY\?\?K89Q^'CR? 5VS>%B[NMLQ C=IS[G5917%5"R@![>K+%SD
M]5N!!+JI&W7*)?A=65,WZA;O>EOK.7\$[J(RE78V\SWT?2.I+,_S\6HI2)?7
M-RU?HJZ6H=RAA2.7(=V%&T)*R_'I&4I#2B 7GK=4#+1#F1"AY'S2 &$ YW.=
MS*;%1V80. _G!5XG"[0W7T@U(P';PW272:+H EMRY9W!(.;;@4!&LA4W+_QR
MVS6;UXR9,_0_!2#@RSN(KNARD/(K%[FZLM*'N1[]41Y!AS#\HH=I#M8B1VA+
MTBI[*77Y9,0I;IP"7"W%YX7B#CM58^')C'$XR_PHB\*B*E==B"7FN.OB*,:X
MK-XX2B3<INM@B#S=&(A<6-B.A%YM%D8\(5][1MS FW0(Q%H%"YRA(#'S3G!Z
M?$L2PL?-I="1W-;I:<BXT7+I%+?45C0U1*O "6]?SUJ\NLC#-Z\+H@%N='_F
MZ^?I!)^-P()ZF<6+R'%7^/)Y@ZZ@.:T*^%(:OB1N3CF:N*SIXAQT4,NV#I_O
ML2AR<3\@R:?FZY5:\A@'U@N)&;,O+9NFY^0\+-TV<(2.MBQ\!!.-RE[2 %7)
MFQO',A1?L@R>$7698D=V/@:3Z?'S[>!H(P:8DQ3)^GE7=&"?]L1J1E9! ZR.
M!'V^%U],7AK"I,P]RY;16W+VJ<8Q<<"=&.$MJ;XA5U;XU-OA4?HW.Y<M/;^W
M>VI8%&-[@*C,K)'BV]JC@@7Y&H$SF95I& '[+B#]KI,JGE(66^?Q MO^1EI$
M0UD"[%]JQZP[Q6+V8B5?##S;8^J/,:MR%A_U,R,BHP6(MO-3TPL'7S7I]Q$D
MKLV(19/+B*=$:*07Z#P>*K"11=_>)ZB>J7=* 2HHFB7D+GPDB@6)%QH%&7RT
ML[^]_T;ZYX?:43$3Q6]5[%>2UQ7+\N<!;C.FUG%R#CI1^6UU"3JE9I&2>%>1
M 5F/5_FQ1S@TK[^WP^<<!ZR^/N\GB=YE?Q_^1H/N.H]DIL=\R@EEG1;E<_UY
M-P<[]"+27,2'<Y_*QM2L&.A,:;-F%&1[!*9Z\"?3 .=.8<X+7XH7<;[S6O+T
MK?UT8G/UPI<F10.2-(H)I+QXBP,#WVW/4R#M58^$BY!S":RL??$##!.M:(]:
MHJW]7(=/H:/C>JU"4U.CW/1;2DL!,'Y&-1%/)H>TIF,)XCUH<(G%A\-"<_3M
M,M=HC&91L_MPVA*]I%^4),RX *UEO)V_'8DP>D[@;1;VZQ,SE$L37=4NL2N5
MK#Y9KWNIV]U@6K6N=V5=6SFT:*P1ADMA_;%-%H[9/"$%W#F-.\H6BKA#EB"%
MM,U='&D4.-9;LSZ:CV_FI&B?$A/A&M+UMS755:E.)-9HI3X^@V*[NX1SNP?W
MM%:%'X1ADOFL<>2!2_DQ/972S<UN)FR9W=H94JQ6'P()AZA*C)EYE8BW6V^^
MEL_79C8"Z$L'PLDY:VEB4\O6BB<*8\UJE\9;;"6;M8R]V+';JBZ<_7G(X3-,
M2[4-R=3B,4\6$MA*?49BF5\(B:/*4*3+*TC)SP-]V&$:;K';"'F2&%X@5C;0
MOO0&, $A@=\*GVYUTAP2(BZGC:LTH MN^Y2*V8QYVBY^@9K+#:A=6V/&;RH4
MU7\4  ZX:BBO&/MC>+YWM%J8GXQZO HJ-!HM[I4T3_V1PU?OH6V!WIV$LL*?
M_PHGL30'Q/1L+#>"\'99V(O]!<5X].;L+8OW^AF)\&->2=]BX\LKD8>N:A:6
M$B>*BV"R.)#">6U_C_P%#V:F=J"8M23"^_.NQG4:\9NS1,%*W!_2 !;-M<<F
M2>&2" @YBEA)90L3TB5NLDF\P!F*$K^Z3=2.<^@P"?!DPFT7,J-MF1%NL76;
M+'Y) >:?L>(#&1)3T5RL,1V2GW/U ]>M(%F9(K/B>F;8 W@+!\6;=$WS?=0"
M4R5GZI(LJ'$4:XN=LRY^60QEEI2,2Y9*U. J+2A97NHU61\@2V,H'-F$\<[3
M[1)*KZ6,4*P9I2I0[,D2Q"-@#)2S:MKS%IAL1)4@W[Y9,R+0R2N:B<$Y7\ 0
M',7:7\\-:+UU?RF]K]$T,$& +41/05\>:<)K7Q,[ ][X_@P2=SUD<8W;)\-4
M@2[1I2&<QOZIJ8GJPWZ0DFS37,GP,0A[[MT3ZZ%K;??&XS_S\2-3]6SF;O80
MAS!VDE+3A,))B-- ZFN-'%+X#[-&R9%]4_,?\90ATC;E"G3_*[GR^#K\["EO
M'=_<)3W3(Z?BFVY]#6<@6;>7,:X)<*5VY8D1MW'/FB21K+ I_2B0YD*I5'LS
M)^E"7> M&^6W/YH?N5M9O%29J9VD 1[T-(H0=X5(9SD(QJJJO1Z/TC%.U=+*
M!@NSO 'M$A+UHUBGP*)AS("$*81YU[]>:2&-!I#L;[0BZ:@L2&H)+$WRNQK&
M^G[/-ZZ1O$)JW'..^9&R?Q^MS>EL5APCX]G?(POAHVSA-DI#J)?<CBWAF=1+
M]H5D:$<MOR0)N:482IK6/T'?(,,(/GSSY/QV7FC4K[+S<PA5:'0P;VULX^T2
MF!^\!WG>(].N,8-MOO3UF)BG+BID.[GU <5S(:&E<_4QSQ,YLC=3DJUT$T'B
M?J*X<4%1B?Z8*T/@HIB!=8*$1$/X\(2N41L5?W3!9Z&6>V6.H3%&HWVLW<_C
MFU!B@HAIOVE<9&$C6!.2NIR=KY$R5AQ7+'NW3UN^MH\&(!JC3H'-/O8D <%!
M@$XZ@2>&"9F=I4]I@(ZC[5C063SZE$>VLYXE5[91I4E_JZ8.?Z_>4MC&-W_8
M)=O1 ([/M^V676 B.;4<4K?LTU,$RDD!;3_/D1@5T9V]L>4\P5>5)(;+P##M
M)HVJ-4<]M+H^>\LSWN 888NTD8>C'V=<B7.LY&0"D,Y582''AV79-D_6$F/V
M8M^R$)*VOE-KC-&Z*F$:I/YQW6!W.&V&-UT-V]4*DB(*[/?\_DT4XW2&_)PT
MO3#0GCU_56!J%X])U!*%5[:BF)H%-U#,,F44G5,FPTB.L&CX3H$YX[-1#+UX
M$T8;3WE;S1ZH@9?;U5QA?^-E^K?4_.L=6M>MB-:<:;[-+A'1C,?T'/JLD&8Q
M9B9#B[712!<-V:+B+8\>]JQDP;19F[I.20CCDF\.!R$7S%<.TNEXPUOMB7R"
MWQ@KCLZ/Q48[["0KO;<<3E<;1G-Q*TN^;%-R/*S"FD^V>-  S^>O*2>3I8/K
M%W.%%KHZKUNWZN\WG.0J1Y*2,HDH@BP&SZ,4IF$R^6O]Z;=PZ7)B1U=T]MVA
MSN2@_>*RZL.K\VZ9WUQWYGWZ?55/89W Z@%3&=N;I9%=X"9?)W^G32/(,Z#W
M6/]?(!*4,[2<+(GX\UA6'<\OWG%R$^MFX]!RS5S2]N,%IS$E*4BF,+)R9F7+
MXOHIAF1HG!F.=_ARJRMKA7)5:"&YLXP7V:H/,B6@+E!XR:V+K$RY9Q?8,;&4
MFT0,02R. I9:LW*?*O#SS+M.',,6=,MFE8!^<7C'YP/@)10 P?M:+T(H^JS"
M-W^*BO)8%_5GC10K!-.<$O$#:Z58E54%E4$MH9)G)-H/,7$CE0YELET$_Z-
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M#U!+ 0(4 Q0    ( ,D[;%,-FF^LNB   !Y, 0 -              "  0
M  !E>%\S,#,X-S<N:'1M4$L! A0#%     @ R3ML4Y%$TS9Q P  )PX  !$
M             ( !Y2   &UB<G@M,C R,3$Q,3(N>'-D4$L! A0#%     @
MR3ML4ZKH.#K_!   Y"\  !4              ( !A20  &UB<G@M,C R,3$Q
M,3)?9&5F+GAM;%!+ 0(4 Q0    ( ,D[;%,A'HI#-@8  (E    5
M      "  ;<I  !M8G)X+3(P,C$Q,3$R7VQA8BYX;6Q02P$"% ,4    " #)
M.VQ3&)K^09H$  #J,   %0              @ $@,   ;6)R>"TR,#(Q,3$Q
M,E]P<F4N>&UL4$L! A0#%     @ R3ML4SUD^89;#@  LU4  !,
M     ( ![30  &UB<G@R,#(Q,3$P-E\X:RYH=&U02P$"% ,4    " #).VQ3
M_"5F_U!   "+2P  '0              @ %Y0P  ;6]L96-U;&EN;&]G;W)E
D<VEZ961C;&5A<BYJ<&=02P4&      < !P#/ 0  !(0

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
